5-year Longitudinal Observational Study of Patients Undergoing Therapy for
IMISC (TARGET-DERM)
Reference NCT03661866
Estimated Study Completion Date December 31, 2026
Target PharmaSolutions, Inc.
​
Brief Summary:
​
TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
For complete details see link below:
Several statewide locations. Contact below to inquire about participation.
​
Contact: Laura Dalfonso 9842340268
Email:
Contact: Laura Malahias 9842340268 ext 209